COMPANY

Medicure

HQ: Princeton, NJ (US office) source · medicure.com ↗

Location: Princeton, NJ (US office) · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Myocardial Infarction Acute Coronary Syndromes Unstable Angina Coronary Artery Bypass Graft Surgery Myocardial Ischemia Reperfusion Injury Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency Tardive Dyskinesia Percutaneous Coronary Intervention Renal Insufficiency Myocardial Revascularization Diabetes Mellitus Type 2 Hypertension Metabolic Syndrome (MC-1) Pyridoxal 5'-phosphate Pyridoxal Phosphate Pyridoxal 5'-Phosphate Tirofiban (Aggrastat) Tirofiban

8Trials (company is sponsor)

Timeline

Feb 16, 2024 Trial start Phase 3: Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency source ↗
2013-01 Trial start Phase 1: Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function source ↗
2012-04 Trial start Phase 2: Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention source ↗
2009-05 Trial start Phase 2: Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia source ↗
2006-11 Trial start Phase 3: A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG source ↗
2004-08 Trial start Phase 2: MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) source ↗
2004-04 Trial start Phase 2: MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery) source ↗

Upcoming milestones

2026-11 (ESTIMATED) · Phase 3 · Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency · NCT04706013

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 8

Record	Title	Phase	Status	Start	Primary completion
NCT04706013	Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency	Phase 3	Recruiting	Feb 16, 2024	2026-11 (estimated)
NCT01522417	Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention	Phase 2	Completed	2012-04	2018-12 (actual)
NCT00917293	Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia	Phase 2	Terminated	2009-05	2012-08 (actual)
NCT01245725	Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention	Phase 3	Withdrawn	Not listed	Not listed
NCT01766154	Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function	Phase 1	Completed	2013-01	2013-02 (actual)
NCT00402506	A Safety and Efficacy Study to Confirm the Cardioprotective Effects of MC-1 in Patients Undergoing High-Risk CABG	Phase 3	Completed	2006-11	Not listed
NCT00157716	MEND-CABG (MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery)	Phase 2	Completed	2004-04	Not listed
NCT00157729	MATCHED (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics)	Phase 2	Completed	2004-08	Not listed